Will birch no longer be a problem? Russia has begun using the first vaccine against allergies — what is known about the Allergarda drug

Deputy Prime Minister Tatyana Golikova announced the start of use of the drug on November 9, 2026.

For people who face endless runny nose, watery eyes, sneezing and nasal congestion every spring, this news could be especially important. Instead of constantly suppressing symptoms, medicine offers to act directly on the mechanism of development of the allergic reaction.

We look into how the new Russian vaccine works, who it is suitable for, and whether it can truly change the lives of allergy sufferers.

What happened: Russia has begun using the Allergarda vaccine

On November 9, 2026, Russian Deputy Prime Minister Tatyana Golikova announced that the domestic vaccine against birch pollen allergy had been registered and had already begun to be used.

The statement was made at the plenary session of the IV International Forum on Nature-Like Technologies at the National Research Center "Kurchatov Institute."

This concerns the drug Allergarda, developed by the National Medical Research Center for Allergology and Immunology of the FMBA of Russia together with the company GENERIUM.

The drug received its registration certificate on September 30, 2026. The developers position it as the world's first recombinant allergy vaccine against birch pollen allergy.

This means that the development has moved from clinical trials to medical use.

How does the new allergy vaccine work?

The main distinguishing feature of Allergarda lies in the technology used to create the drug.

Traditional allergen-specific immunotherapy (ASIT) involves the gradual administration to the patient of controlled doses of the allergen. The goal is to teach the immune system to react more calmly to the substance that previously caused an allergic reaction.

The new Russian development uses a recombinant genetically engineered construct.

It is based on specially selected protein fragments associated with the main birch pollen allergens.

This technology makes it possible to influence the immune response more selectively.

The main objective of the drug is to form immunological tolerance to the allergen so that the body stops reacting to contact with pollen with such pronounced allergic symptoms.

Thus, this is not simply about temporarily eliminating a runny nose or itchy eyes, but about an attempt to change the very mechanism of the allergic reaction.

What did the clinical trials show?

One of the most important questions remains the effectiveness of the new development.

According to published clinical trial data, the drug demonstrated a statistically significant reduction in the combined indicator of allergy symptom severity and the need for anti-allergy medications.

In the group receiving the 80 mcg dosage, this indicator was 24.13% lower than in the placebo group.

For the 40 mcg dosage, the reduction was 17.41%.

In addition, the researchers recorded an increase in the level of protective IgG antibodies, which are capable of blocking the interaction of the allergen with the immune system.

The developers also reported a favorable safety profile of the drug in the studies conducted.

At the same time, it is important to understand: the results of clinical trials do not mean that the vaccine will guaranteed completely rid every patient of allergies. Effectiveness may vary depending on individual characteristics of the body.

Who is the Allergarda vaccine suitable for?

According to information from the developers and registration data, the drug is intended for adult patients over 18 years of age.

Main indications:

• confirmed birch pollen allergy;
• seasonal allergic rhinitis;
• allergic conjunctivitis;
• concomitant cross-reactive food allergy associated with sensitization to birch pollen.

The last point is especially interesting.

Some people with birch allergy experience reactions to certain foods. This is because the proteins in some fruits and other foods are similar to pollen proteins.

As a result, the immune system may react not only to flowering trees but also to the consumption of certain foods.

Among the possible food triggers mentioned are apples, pears, peaches, soy and peanuts.

The developers are also considering the drug's effect on this mechanism of cross-allergy.

How many injections will be required?

Unlike the common perception of vaccines as a single preventive injection, Allergarda involves a full course of therapy.

According to published data, the course includes up to five subcutaneous injections with intervals of approximately one month.

The last injection is planned to be administered before the start of the birch flowering season.

This allows the body to form the necessary immune response before the period of most intensive contact with the allergen.

The administration of the drug must be carried out exclusively in a medical organization under the supervision of specialists.

It is not permissible to purchase and use such a vaccine independently without consulting an allergist.

When will Russians be able to receive the vaccine?

According to the FMBA, after registration of the drug in autumn 2026, it was planned to provide the vaccine to tens of thousands of patients.

This will allow some allergy sufferers to complete a course of therapy before the next birch flowering season in 2027.

However, the mass availability of the drug, its cost and the possibility of obtaining it under the compulsory medical insurance policy require separate clarification.

As of today, one should not count on the vaccine automatically becoming free for all patients with seasonal allergies.

Why is this an important step for Russian medicine?

Tree pollen allergy remains one of the common causes of seasonal allergic rhinitis.

For many people, spring turns into a period of constant discomfort: nasal congestion, sneezing, eye irritation and sleep disturbances significantly affect quality of life.

Traditional antihistamines help control symptoms but do not eliminate the underlying cause of the immune system's heightened sensitivity.

Allergen-specific immunotherapy offers a different approach — the formation of more stable tolerance to the allergen.

The emergence of the recombinant Allergarda vaccine may expand the possibilities of such treatment and become an important stage in the development of domestic allergology.

What happens next?

The next important stage is the accumulation of results from the use of the drug in real medical practice.

Specialists will need to assess the effectiveness of the therapy in a broader range of patients, the duration of the effect obtained and the safety of use in the long term.

The birch flowering season in spring 2027 will be especially indicative.

That is when it will be possible to assess how well the formed immunological tolerance protects patients from seasonal allergic manifestations.

Bottom line: can the new vaccine defeat spring allergies?

The emergence of Allergarda is a notable event for Russian medicine.

For the first time, a domestic recombinant allergy vaccine against birch pollen has received registration and moved to practical use.

For millions of people who face seasonal allergies every year, this opens a new treatment prospect.

However, it is still premature to call the drug a universal cure for allergies. It is intended for specific indications, has age restrictions and requires a doctor's prescription.

The main question is how effective the vaccine will prove to be in the upcoming birch flowering season in 2027. If the clinical trial results are confirmed in broad medical practice, the approach to treating seasonal allergies could change significantly.

The Pulse editorial team will continue to follow the development of the Russian medical product.